The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Medical News Today has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations. We only use quality, credible sources ...

In November 2023, the U.S Food and Drug Administration ... It should be used with a reduced-calorie diet and increased ...

Zepbound only fully came off the official FDA drug shortage list less than 2 months ago. Taking any of the new weight loss drugs – like Zepbound, or a similar one called Wegovy – has required ...

Oct 2 (Reuters) - The U.S. Food and Drug Administration ... been on the health regulator's shortage list since late 2022, while weight-loss drug Zepbound was added in April as demand far ...

The world's biggest food company is targeting Ozempic users with small, protein-packed meals for under $5.

The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis of the clinical trials that led to its approval. All doses of tirzepatide ...

The Food and Drug Administration said late Wednesday ... Tirzepatide was approved as Zepbound in late 2023 as a weight-loss treatment.